Immunosuppression bei Handtransplantation: State of the Art, Zukunftsperspektiven

Avoidance or minimization of maintenance immunosuppression represents the key step for promoting wider applicability of reconstructive transplantation. Understanding the mechanisms of composite tissue allograft rejection is of essence in working towards this goal. We herein review the current knowledge on acute rejection in reconstructive transplantation and discuss findings in the light of novel immunosuppressive and immunomodulatory strategies.

[1]  Frédéric Schuind,et al.  The International Registry on Hand and Composite Tissue Transplantation , 2010, Transplantation.

[2]  R. Margreiter,et al.  Alemtuzumab: key for minimization of maintenance immunosuppression in reconstructive transplantation? , 2009, Transplantation proceedings.

[3]  R. Margreiter,et al.  Immunosuppression and rejection in human hand transplantation. , 2009, Transplantation proceedings.

[4]  R. Margreiter,et al.  The Innsbruck hand transplant program: update at 8 years after the first transplant. , 2009, Transplantation proceedings.

[5]  R. Margreiter,et al.  Infectious complications in three double hand recipients: experience from a single center. , 2009, Transplantation Proceedings.

[6]  J. Bouwes Bavinck,et al.  Melanoma in Organ Transplant Recipients: Clinicopathological Features and Outcome in 100 Cases , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  A. Kirk,et al.  The Banff 2007 Working Classification of Skin‐Containing Composite Tissue Allograft Pathology , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  F. Schuind,et al.  Atypical Acute Rejection After Hand Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  V. Sharma,et al.  HLA-mismatched renal transplantation without maintenance immunosuppression. , 2008, The New England journal of medicine.

[10]  T. Starzl.  Immunosuppressive therapy and tolerance of organ allografts. , 2008, The New England journal of medicine.

[11]  A. Sirigu,et al.  Outcomes 18 months after the first human partial face transplantation. , 2007, The New England journal of medicine.

[12]  Nina Singh,et al.  Alternaria alternata soft tissue infection in a forearm transplant recipient. , 2007, Surgical infections.

[13]  F. Schuind,et al.  Second report (1998-2006) of the International Registry of Hand and Composite Tissue Transplantation. , 2007, Transplant immunology.

[14]  R. Margreiter,et al.  First Forearm Transplantation: Outcome at 3 Years , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  R. Margreiter,et al.  Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  K. Kabashima,et al.  Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin , 2006, Clinical and experimental immunology.

[17]  F. Schuind,et al.  The First Belgian Hand Transplantation—37 Month Term Results , 2006, Journal of hand surgery.

[18]  A. Sirigu,et al.  Bilateral Hand Transplantation: Six Years After the First Case , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  R. Margreiter,et al.  Status 5 Years after Bilateral Hand Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  F. Baldanti,et al.  Cytomegalovirus-Related Complications in Human Hand Transplantation , 2005, Transplantation.

[21]  R. Margreiter,et al.  Steroid‐ and ATG‐Resistant Rejection After Double Forearm Transplantation Responds to Campath‐1H , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  J. Dubernard,et al.  The International Registry On Hand And Composite Tissue Allograft , 2004 .

[23]  M. Mannie,et al.  MHC class II biosynthesis by activated rat CD4+ T cells: development of repression in vitro and modulation by APC-derived signals. , 2004, Cellular immunology.

[24]  B. Kasiske,et al.  Cancer after Kidney Transplantation in the United States , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  Yanqing Ding,et al.  A preliminary pathological study on human allotransplantation. , 2003, Chinese journal of traumatology = Zhonghua chuang shang za zhi.

[26]  Jean Kanitakis,et al.  Clinicopathologic features of graft rejection of the first human hand allograft , 2003, Transplantation.

[27]  M. Luppi,et al.  Skin cancers after organ transplantation. , 2003, The New England journal of medicine.

[28]  S. Light,et al.  Long‐term Safety, Tolerability and Efficacy of Daclizumab (Zenapax®) in a Two‐dose Regimen in Liver Transplant Recipients , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  D. Olive,et al.  Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. , 2002, Blood.

[30]  R. Margreiter,et al.  [Bilateral hand transplantation]. , 2002, Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V....

[31]  C. Larsen,et al.  The Role of the IL-2 Pathway in Costimulation Blockade-Resistant Rejection of Allografts1 , 2002, The Journal of Immunology.

[32]  H. Uchi,et al.  Cytokines and chemokines in the epidermis. , 2000, Journal of dermatological science.

[33]  S. Birkeland,et al.  Cancer risk in patients on dialysis and after renal transplantation , 2000, The Lancet.

[34]  Jean Kanitakis,et al.  Sequential histological and immunohistochemical study of the skin of the first human hand allograft. , 2000, Transplantation.

[35]  M. Lanzettà,et al.  Human hand allograft: report on first 6 months , 1999, The Lancet.

[36]  H. Meier‐Kriesche,et al.  Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation , 1998 .

[37]  S. Sehgal.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. , 1998, Clinical biochemistry.

[38]  T. Mathew.  A Blinded, Long-term, Randomized Multicenter Study Of Mycophenolate Mofetil In Cadaveric Renal Transplantation: Results at Three Years1,2 , 1998 .

[39]  P. Barnes,et al.  Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.

[40]  E. C. Harris,et al.  Suicide as an Outcome for Medical Disorders , 1994, Medicine.

[41]  V. Barnaba,et al.  Professional presentation of antigen by activated human T cells , 1994, European journal of immunology.

[42]  A. Allison,et al.  Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil , 1993, Immunological reviews.

[43]  L. Glimcher,et al.  The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Sercarz,et al.  Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection , 1992, The Journal of experimental medicine.

[45]  P. Botham,et al.  The expression of MHC class II (Ia) antigens on mouse keratinocytes following epicutaneous application of contact sensitizers and irritants , 1991, The British journal of dermatology.

[46]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[47]  A. Gaspari,et al.  Induction and functional characterization of class II MHC (Ia) antigens on murine keratinocytes. , 1988, Journal of immunology.

[48]  J. Czernielewski,et al.  Class II MHC antigen expression by human keratinocytes results from lympho-epidermal interactions and gamma-interferon production. , 1986, Clinical and experimental immunology.

[49]  R. Lechler,et al.  Why MHC incompatible grafts induce strong primary alloimmunity. , 1982, Transplantation proceedings.

[50]  R. Lechler,et al.  Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells , 1982, The Journal of experimental medicine.

[51]  Melvin Cohn,et al.  A Theory of Self-Nonself Discrimination , 1970, Science.

[52]  T. Pruett.  Cytomegalovirus-Related Complications in Human Hand Transplantation , 2007 .

[53]  S. Cobbold.  New trends in immunosuppression. , 2005, International immunopharmacology.

[54]  V. Gorantla,et al.  Immunosuppressive agents in transplantation: Mechanisms of action and current anti‐rejection strategies , 2000, Microsurgery.

[55]  S. Gruber,et al.  Successful hand transplantation. One-year follow-up. Louisville Hand Transplant Team. , 2000, The New England journal of medicine.

[56]  M. Hardy,et al.  Immunologic considerations in composite tissue transplantation: Overview , 2000, Microsurgery.

[57]  R. Lechler,et al.  The structural basis of alloreactivity , 1990, Immunologic research.